IFP Advisors Inc Has $390,000 Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

IFP Advisors Inc cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 7.8% during the 4th quarter, Holdings Channel reports. The firm owned 20,768 shares of the biotechnology company’s stock after selling 1,745 shares during the quarter. IFP Advisors Inc’s holdings in Arrowhead Pharmaceuticals were worth $390,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of ARWR. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its stake in shares of Arrowhead Pharmaceuticals by 79.6% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 14,498 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 6,424 shares during the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in shares of Arrowhead Pharmaceuticals by 4.4% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 37,844 shares of the biotechnology company’s stock worth $737,000 after buying an additional 1,609 shares during the period. State of Alaska Department of Revenue boosted its holdings in shares of Arrowhead Pharmaceuticals by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company’s stock worth $279,000 after buying an additional 980 shares during the period. Finally, abrdn plc boosted its holdings in shares of Arrowhead Pharmaceuticals by 61.3% during the 3rd quarter. abrdn plc now owns 401,146 shares of the biotechnology company’s stock worth $7,770,000 after buying an additional 152,476 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ARWR. Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Piper Sandler reduced their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Citigroup reduced their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Wednesday, November 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $41.44.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the completion of the sale, the director now owns 36,740 shares of the company’s stock, valued at approximately $734,800. This represents a 7.20 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider James C. Hamilton sold 32,729 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $19.82, for a total transaction of $648,688.78. Following the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at approximately $5,393,458.04. This trade represents a 10.74 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 147,432 shares of company stock valued at $2,957,986. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $18.91 on Friday. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27. The company has a market capitalization of $2.38 billion, a P/E ratio of -3.66 and a beta of 0.95. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $17.05 and a 12-month high of $36.72. The firm has a 50-day moving average price of $19.60 and a two-hundred day moving average price of $20.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.